CGIM
CODX

Cannon Global Investment Management’s Co-Diagnostics CODX Stock Holding History

Cannon Global Investment Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-547
Closed -$135K – 55
2021
Q2 		$135K Buy
+547
New +$141K 0.26% 39

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cannon Global Investment Management's CODX Position: Q3 2021 in Review

Cannon Global Investment Management sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 547 shares — an estimated $135K sold.

Cannon Global Investment Management first reported a position in CODX in Q2 2021 and held it in 1 quarter. The position peaked at $135K in Q2 2021. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

  • Cannon Global Investment Management reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Cannon Global Investment Management sold 547 Co-Diagnostics shares in Q3 2021, an estimated $135K.
  • Cannon Global Investment Management first reported a position in Co-Diagnostics in Q2 2021 and held it in 1 quarter.
  • Cannon Global Investment Management's Co-Diagnostics position peaked at $135K in Q2 2021.
  • 78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on Cannon Global Investment Management's 13F filing for Q3 2021, filed 27 Oct 2021.